Products Categories
CAS No.: | 11056-06-7 |
---|---|
Name: | Bleomycin |
Article Data: | 7 |
Molecular Structure: | |
Formula: | Unspecified |
Molecular Weight: | 2927.17 |
Synonyms: | Bleo;Bleocin;NSC 125066;Blenamax; |
EINECS: | 232-925-2 |
Solubility: | Soluble |
Appearance: | powder |
Hazard Symbols: | T |
Risk Codes: | 46-40 |
Safety: | 53-36/37-45 |
PSA: | 794.66000 |
LogP: | -1.89040 |
Bleomycin (11056-06-7) was first discovered in 1966 when the Japanese scientist Hamao Umezawa found anti-cancer activity while screening culture filtrates of S. verticullus,and it was published his discovery by Umezawa in 1966.The drug was launched in Japan by Nippon Kayaku in 1969. In the US it gained FDA approval in July 1973.And it was initially marketed in the US under the brand name Blenoxane.The biosynthesis of the Bleomycin aglycon can be easily visualized in three stages: Fitst: NRPS-mediated formation of P-3A from Ser, Asn, His, and Ala.scecond: PKS-mediated elongation of P-3A by malonyl CoA and AdoMet to yield P-4.At last: NRPS-mediated elongation of P-4 by Thr to P-5 that is further elongated by ß-Ala, Cys, and Cys to get P-6m.
IARC Cancer Review: Group 2B IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man 7 (1987),p. 134.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man 26 (1981),p. 97.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) . EPA Genetic Toxicology Program.